Cargando…
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious and pathogenic virus that first appeared in late December 2019. This SARS-CoV-2 causes an infection of an acute respiratory disease called “coronavirus infectious disease-2019 (COVID-19). The World Health Organizatio...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946785/ https://www.ncbi.nlm.nih.gov/pubmed/36855648 http://dx.doi.org/10.1016/j.heliyon.2023.e13952 |
_version_ | 1784892408871256064 |
---|---|
author | Hillary, Varghese Edwin Ceasar, Stanislaus Antony |
author_facet | Hillary, Varghese Edwin Ceasar, Stanislaus Antony |
author_sort | Hillary, Varghese Edwin |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious and pathogenic virus that first appeared in late December 2019. This SARS-CoV-2 causes an infection of an acute respiratory disease called “coronavirus infectious disease-2019 (COVID-19). The World Health Organization (WHO) declared this SARS-CoV-2 outbreak a great pandemic on March 11, 2020. As of January 31, 2023, SARS-CoV-2 recorded more than 67 million cases and over 6 million deaths. Recently, novel mutated variants of SARS-CoV are also creating a serious health concern worldwide, and the future novel variant is still mysterious. As infection cases of SARS-CoV-2 are increasing daily, scientists are trying to combat the disease using numerous antiviral drugs and vaccines against SARS-CoV-2. To our knowledge, this is the first comprehensive review that summarized the dynamic nature of SARS-CoV-2 transmission, SARS-CoV-2 variants (a variant of concern and variant of interest), antiviral drugs and vaccines utilized against SARS-CoV-2 at a glance. Hopefully, this review will enable the researcher to gain knowledge on SARS-CoV-2 variants and vaccines, which will also pave the way to identify efficient novel vaccines against forthcoming SARS-CoV-2 strains. |
format | Online Article Text |
id | pubmed-9946785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-99467852023-02-23 An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines Hillary, Varghese Edwin Ceasar, Stanislaus Antony Heliyon Review Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious and pathogenic virus that first appeared in late December 2019. This SARS-CoV-2 causes an infection of an acute respiratory disease called “coronavirus infectious disease-2019 (COVID-19). The World Health Organization (WHO) declared this SARS-CoV-2 outbreak a great pandemic on March 11, 2020. As of January 31, 2023, SARS-CoV-2 recorded more than 67 million cases and over 6 million deaths. Recently, novel mutated variants of SARS-CoV are also creating a serious health concern worldwide, and the future novel variant is still mysterious. As infection cases of SARS-CoV-2 are increasing daily, scientists are trying to combat the disease using numerous antiviral drugs and vaccines against SARS-CoV-2. To our knowledge, this is the first comprehensive review that summarized the dynamic nature of SARS-CoV-2 transmission, SARS-CoV-2 variants (a variant of concern and variant of interest), antiviral drugs and vaccines utilized against SARS-CoV-2 at a glance. Hopefully, this review will enable the researcher to gain knowledge on SARS-CoV-2 variants and vaccines, which will also pave the way to identify efficient novel vaccines against forthcoming SARS-CoV-2 strains. Elsevier 2023-02-23 /pmc/articles/PMC9946785/ /pubmed/36855648 http://dx.doi.org/10.1016/j.heliyon.2023.e13952 Text en © 2023 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Article Hillary, Varghese Edwin Ceasar, Stanislaus Antony An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines |
title | An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines |
title_full | An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines |
title_fullStr | An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines |
title_full_unstemmed | An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines |
title_short | An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines |
title_sort | update on covid-19: sars-cov-2 variants, antiviral drugs, and vaccines |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946785/ https://www.ncbi.nlm.nih.gov/pubmed/36855648 http://dx.doi.org/10.1016/j.heliyon.2023.e13952 |
work_keys_str_mv | AT hillaryvargheseedwin anupdateoncovid19sarscov2variantsantiviraldrugsandvaccines AT ceasarstanislausantony anupdateoncovid19sarscov2variantsantiviraldrugsandvaccines AT hillaryvargheseedwin updateoncovid19sarscov2variantsantiviraldrugsandvaccines AT ceasarstanislausantony updateoncovid19sarscov2variantsantiviraldrugsandvaccines |